Does GILTERITINIB Cause Myelosuppression? 300 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 300 reports of Myelosuppression have been filed in association with GILTERITINIB (Xospata). This represents 8.2% of all adverse event reports for GILTERITINIB.
300
Reports of Myelosuppression with GILTERITINIB
8.2%
of all GILTERITINIB reports
75
Deaths
114
Hospitalizations
How Dangerous Is Myelosuppression From GILTERITINIB?
Of the 300 reports, 75 (25.0%) resulted in death, 114 (38.0%) required hospitalization, and 27 (9.0%) were considered life-threatening.
Is Myelosuppression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for GILTERITINIB. However, 300 reports have been filed with the FAERS database.
What Other Side Effects Does GILTERITINIB Cause?
Acute myeloid leukaemia (366)
Febrile neutropenia (346)
Off label use (334)
Platelet count decreased (327)
Pneumonia (302)
Pyrexia (281)
Death (206)
Product use issue (189)
Hepatic function abnormal (181)
Neutrophil count decreased (162)
What Other Drugs Cause Myelosuppression?
CYCLOPHOSPHAMIDE (3,603)
CARBOPLATIN (2,624)
TRASTUZUMAB (2,552)
PACLITAXEL (2,522)
TISLELIZUMAB (2,142)
CYTARABINE (1,869)
VENETOCLAX (1,864)
CISPLATIN (1,849)
BEVACIZUMAB (1,744)
SODIUM (1,696)
Which GILTERITINIB Alternatives Have Lower Myelosuppression Risk?
GILTERITINIB vs GIMERACIL\OTERACIL\TEGAFUR
GILTERITINIB vs GINKGO
GILTERITINIB vs GIVINOSTAT
GILTERITINIB vs GIVOSIRAN
GILTERITINIB vs GLASDEGIB